Antibody formulations
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Feb 12, 2013
Grant Date -
Jan 21, 2010
app pub date -
Sep 4, 2009
filing date -
Oct 20, 2004
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
The present application describes antibody formulations, including monoclonal antibodies formulated in histidine-acetate buffer, as well as a formulation comprising an antibody that binds to domain II of HER2 (for example, Pertuzumab), and a formulation comprising an antibody that binds to DR5 (for example, Apomab).
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully